<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Antiviral ResAntiviral ResAntiviral Research0166-35421872-9096Elsevier B.V. S0166-3542(20)30205-9 doi: 10.1016/j.antiviral.2020.104791104791 : Article" exact="Type 1" post="interferons as a potential treatment against COVID-19 SallardErwanaLescureFranÃ§ois-XavierbcYazdanpanahYazdanbcMentreFrancebPeiffer-SmadjaNathannathan.peiffer-smadja@inserm.frbcâˆ—[a], [b],"/>
 <result pre="treatment against COVID-19 SallardErwanaLescureFranÃ§ois-XavierbcYazdanpanahYazdanbcMentreFrancebPeiffer-SmadjaNathannathan.peiffer-smadja@inserm.frbcâˆ—[a], [b], [c], âˆ—Corresponding author. Department of" exact="Infectious" post="and Tropical Diseases, Assistance Publique - HÃ´pitaux de Paris,"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Type 1" post="interferons have a broad antiviral activity in vitro and"/>
 <result pre="review, we discuss preliminary data concerning the potential activity of" exact="type 1" post="interferons on SARS-CoV-2, and the relevance of evaluating these"/>
 <result pre="contain the epidemics. Several candidates are already being investigated, including" exact="type 1" post="interferon (IFNâ€&quot;I) (Martinez, 2020; Belhadi et al., 2020). Indeed,"/>
 <result pre="Belhadi et al., 2020). Indeed, in the context of emerging" exact="viral" post="infections, IFN-I are often evaluated (usually in combination with"/>
 <result pre="treatment of coronaviruses and to discuss its potential in SARS-CoV-2." exact="Type 1" post="interferons (IFNâ€&quot;I) designate a group of cytokines comprising the"/>
 <result pre="various cell types, notably plasmacytoid dendritic cells, upon recognition of" exact="viral" post="components by pattern recognition receptors (PRR) (Liu, 2005). IFN-I"/>
 <result pre="IFN-I are thus among the first cytokines produced during a" exact="viral infection." post="They are recognized by the IFNAR receptor present at"/>
 <result pre="are involved in inflammation, signaling and immunomodulation. They interfere with" exact="viral" post="replication and spread by several mechanisms such as a"/>
 <result pre="the cell to pathogens, proteins which decrease membrane fluidity, preventing" exact="viral" post="egress or membrane fusion, and antivirals that specifically inhibit"/>
 <result pre="fusion, and antivirals that specifically inhibit one step of the" exact="viral" post="cycle (Schneider et al., 2014; Totura and Baric, 2012)."/>
 <result pre="more than 20 years for the treatment of patients with" exact="multiple sclerosis." post="The role of IFNÎ² in the treatment of multiple"/>
 <result pre="multiple sclerosis. The role of IFNÎ² in the treatment of" exact="multiple sclerosis" post="is still debated and likely results partly from the"/>
 <result pre="et al., 2015), but generally failed to significantly improve the" exact="disease" post="in humans (Stockman et al., 2006). For example, a"/>
 <result pre="example, a combination of IFNÎ² with lopinavir/ritonavir against MERS-CoV improved" exact="pulmonary" post="function but did not significantly reduce virus replication or"/>
 <result pre="in human (Arabi et al., 2017). The lack of significant" exact="disease" post="improvement with IFN-I treatment in numerous studies can be"/>
 <result pre="IFN signaling pathway used by MERS-CoV and SARS-CoV, by the" exact="limited" post="number of patients or animals used in the studies,"/>
 <result pre="in the studies, or by the difficulty to decipher whether" exact="disease" post="improvements were caused by IFN-I or the drugs used"/>
 <result pre="the lung: it up-regulates cluster of differentiation 73 (CD73) in" exact="pulmonary" post="endothelial cells, resulting in the secretion of anti-inflammatory adenosine"/>
 <result pre="This process explains why clinical data indicate a reduction of" exact="vascular" post="leakage in acute respiratory distress syndrome (ARDS) with IFNÎ²1a"/>
 <result pre="why clinical data indicate a reduction of vascular leakage in" exact="acute" post="respiratory distress syndrome (ARDS) with IFNÎ²1a treatment (Bellingan et"/>
 <result pre="clinical data indicate a reduction of vascular leakage in acute" exact="respiratory" post="distress syndrome (ARDS) with IFNÎ²1a treatment (Bellingan et al.,"/>
 <result pre="indicate a reduction of vascular leakage in acute respiratory distress" exact="syndrome" post="(ARDS) with IFNÎ²1a treatment (Bellingan et al., 2014). However,"/>
 <result pre="was administered shortly after infection, but IFN-I failed to inhibit" exact="viral" post="replication and had side-effects when administered later (Channappanavar et"/>
 <result pre="2020): although SARS-CoV-2 replication is not entirely suppressed by interferons," exact="viral" post="titers are decreased by several orders of magnitude. SARS-CoV2"/>
 <result pre="hypothesis, it was shown that IFNÎ±2b sprays can reduce the" exact="infection" post="rate of SARS-CoV-2 (Shen and Yang, 2020). This study"/>
 <result pre="might be a safe and efficient treatment against SARS-CoV-2. Knowledge" exact="acquired" post="during studies on MERS-CoV or SARS-CoV would be critical"/>
 <result pre="(Channappanavar et al., 2019). Furthermore, COVID-19 pathology, mainly consisting in" exact="pulmonary" post="lesions, presents similar characteristics with interferonopathies: it may suggest"/>
 <result pre="antiviral response, leading to tissue damage. IFN-I treatment should be" exact="limited" post="to the early phases of the infection if this"/>
 <result pre="treatment should be limited to the early phases of the" exact="infection" post="if this hypothesis is confirmed, as suggested in (Siddiqi"/>
 <result pre="performed in China offers the advantage of targeting specifically the" exact="respiratory" post="tract; however, to the best of our knowledge, the"/>
 <result pre="et al., 2020). It might also be relevant to evaluate" exact="type III" post="IFN for the treatment of COVID-19 (Lokugamage et al.,"/>
 <result pre="of the protective effects of this interferon type in the" exact="respiratory" post="tract. Subcutaneous IFNÎ²1a in combination with lopinavir/ritonavir is compared"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: an observational studyInt. J. Infect. Dis.202014424610.1016/j.ijid.2013.12.00324406736 ArabiY.M.ShalhoubS.Al-OmariA.MandourahY.Al-HameedF.SindiA.AlraddadiB.Al-MotairiA.Al-KhatibK.Abdul-MomminA.QushmaqI.A.MadyA.SolaimanO.Al-AithanA.BalkhyH.H.Al-RaddadiR.RajabA.Al-MekhlafiG.A.Al-HarthyA.KharabaA.Al-JabbaryA.PintoR.SadatM.Al-MutairiH.Al-QasimE.JoseJ.DeebA.M.MersonL.HaydenF.G.FowlerR.AldawoodA.S.Effect"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: an observational studyInt. J. Infect. Dis.202014424610.1016/j.ijid.2013.12.00324406736 ArabiY.M.ShalhoubS.Al-OmariA.MandourahY.Al-HameedF.SindiA.AlraddadiB.Al-MotairiA.Al-KhatibK.Abdul-MomminA.QushmaqI.A.MadyA.SolaimanO.Al-AithanA.BalkhyH.H.Al-RaddadiR.RajabA.Al-MekhlafiG.A.Al-HarthyA.KharabaA.Al-JabbaryA.PintoR.SadatM.Al-MutairiH.Al-QasimE.JoseJ.DeebA.M.MersonL.HaydenF.G.FowlerR.AldawoodA.S.Effect of"/>
 <result pre="AlAwadS.CabalR.C.OnaziB. AlAljuhaniM.VinceM.EnaniM. AlAlqurashiA.AleneziF.AlkhaniN.ThaqafiA.OraabiO. AlRifaiJ.ElsamadisiP.MedhatS.H.BasherS.A.B.AbduldhaherM.BajhamoumW.AlahsaS.S.BashirS.Al-DossaryI.Al-Muhainy DammamB.KhobarS.S. AlAlshahraniM.S.Al JabriA.FaridM.AlaidarousA.AlseraihiW.ShahadaH.TaifJ.S.Treatment of Middle East" exact="Respiratory" post="Syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE"/>
 <result pre="AlAljuhaniM.VinceM.EnaniM. AlAlqurashiA.AleneziF.AlkhaniN.ThaqafiA.OraabiO. AlRifaiJ.ElsamadisiP.MedhatS.H.BasherS.A.B.AbduldhaherM.BajhamoumW.AlahsaS.S.BashirS.Al-DossaryI.Al-Muhainy DammamB.KhobarS.S. AlAlshahraniM.S.Al JabriA.FaridM.AlaidarousA.AlseraihiW.ShahadaH.TaifJ.S.Treatment of Middle East Respiratory" exact="Syndrome" post="with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 <result pre="of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on" exact="acute" post="respiratory distress syndrome mortality: an open-label studyLancet Respir. Med.220149810710.1016/S2213-2600(13)70259-524503265"/>
 <result pre="intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute" exact="respiratory" post="distress syndrome mortality: an open-label studyLancet Respir. Med.220149810710.1016/S2213-2600(13)70259-524503265 BelhadiD.Peiffer-SmadjaN.YazdanpanahY.MentrÃ©F.LaouÃ©nanC.A"/>
 <result pre="(FP-1201) on lung CD73 expression and on acute respiratory distress" exact="syndrome" post="mortality: an open-label studyLancet Respir. Med.220149810710.1016/S2213-2600(13)70259-524503265 BelhadiD.Peiffer-SmadjaN.YazdanpanahY.MentrÃ©F.LaouÃ©nanC.A brief review"/>
 <result pre="for COVID-19. medRxivJanuary202010.1101/2020.03.18.200381902020.03.18.20038190 ChanJ.F.W.ChanK.H.KaoR.Y.T.ToK.K.W.ZhengB.J.LiC.P.Y.LiP.T.W.DaiJ.MokF.K.Y.ChenH.HaydenF.G.YuenK.Y.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 ChanJ.F.W.YaoY.YeungM.L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.P.ChuH.ZhouJ.ChenH.QinC.YuenK.Y.Treatment with lopinavir/ritonavir or interferon-Î²1b improves"/>
 <result pre="COVID-19. medRxivJanuary202010.1101/2020.03.18.200381902020.03.18.20038190 ChanJ.F.W.ChanK.H.KaoR.Y.T.ToK.K.W.ZhengB.J.LiC.P.Y.LiP.T.W.DaiJ.MokF.K.Y.ChenH.HaydenF.G.YuenK.Y.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 ChanJ.F.W.YaoY.YeungM.L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.P.ChuH.ZhouJ.ChenH.QinC.YuenK.Y.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome"/>
 <result pre="Infect.67201360661610.1016/j.jinf.2013.09.02924096239 ChanJ.F.W.YaoY.YeungM.L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.P.ChuH.ZhouJ.ChenH.QinC.YuenK.Y.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERSCoV" exact="infection" post="in a nonhuman primate model of common marmosetJ. Infect."/>
 <result pre="ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Invest.12920193625363910.1172/JCI12636331355779 ChenF.ChanK.H.JiangY.KaoR.Y.T.LuH.T.FanK.W.ChengV.C.C.TsuiW.H.W.HungI.F.N.LeeT.S.W.GuanY.PeirisJ.S.M.YuenK.Y.In vitro susceptibility of 10 clinical"/>
 <result pre="selected antiviral compoundsJ. Clin. Virol.312004697510.1016/j.jcv.2004.03.00315288617 DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.142020586010.5582/ddt.2020.0101232147628 FalzaranoD.De WitE.MartellaroC.CallisonJ.MunsterV.J.FeldmannH.Inhibition of novel Î²"/>
 <result pre="replication by a combination of interferon-Î±2b and ribavirinSci. Rep.320131610.1038/srep01686 FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe" exact="acute" post="respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering"/>
 <result pre="by a combination of interferon-Î±2b and ribavirinSci. Rep.320131610.1038/srep01686 FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe acute" exact="respiratory" post="syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear"/>
 <result pre="a combination of interferon-Î±2b and ribavirinSci. Rep.320131610.1038/srep01686 FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe acute respiratory" exact="syndrome" post="coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import"/>
 <result pre="of low-dose recombinant human interferons Î±-2b nasal spray to prevent" exact="acute" post="viral respiratory infections in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-Î² and mycophenolic"/>
 <result pre="low-dose recombinant human interferons Î±-2b nasal spray to prevent acute" exact="viral" post="respiratory infections in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-Î² and mycophenolic acid"/>
 <result pre="recombinant human interferons Î±-2b nasal spray to prevent acute viral" exact="respiratory" post="infections in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-Î² and mycophenolic acid are"/>
 <result pre="human interferons Î±-2b nasal spray to prevent acute viral respiratory" exact="infections" post="in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-Î² and mycophenolic acid are potent"/>
 <result pre="HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-Î² and mycophenolic acid are potent inhibitors of middle east" exact="respiratory" post="syndrome coronavirus in cell-based assaysJ. Gen. Virol.95201457157710.1099/vir.0.061911-024323636 HensleyL.E.FritzE.A.JahrlingP.B.KarpC.L.HugginsJ.W.GeisbertT.W.Interferon-Î² 1a"/>
 <result pre="and mycophenolic acid are potent inhibitors of middle east respiratory" exact="syndrome" post="coronavirus in cell-based assaysJ. Gen. Virol.95201457157710.1099/vir.0.061911-024323636 HensleyL.E.FritzE.A.JahrlingP.B.KarpC.L.HugginsJ.W.GeisbertT.W.Interferon-Î² 1a and"/>
 <result pre="JakimovskiD.KolbC.RamanathanM.ZivadinovR.Weinstock-GuttmanB.Interferon Î² for multiple sclerosisCold Spring Harb. Perspect. Med.8201812010.1101/cshperspect.a032003 Kopecky-BrombergS.A.Martinez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe" exact="acute" post="respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF"/>
 <result pre="Î² for multiple sclerosisCold Spring Harb. Perspect. Med.8201812010.1101/cshperspect.a032003 Kopecky-BrombergS.A.Martinez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe acute" exact="respiratory" post="syndrome coronavirus open reading frame (ORF) 3b, ORF 6,"/>
 <result pre="for multiple sclerosisCold Spring Harb. Perspect. Med.8201812010.1101/cshperspect.a032003 Kopecky-BrombergS.A.Martinez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe acute respiratory" exact="syndrome" post="coronavirus open reading frame (ORF) 3b, ORF 6, and"/>
 <result pre="6, and nucleocapsid proteins function as interferon antagonistsJ. Virol.81200754855710.1128/jvi.01782-0617108024 LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="and nucleocapsid proteins function as interferon antagonistsJ. Virol.81200754855710.1128/jvi.01782-0617108024 LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
 <result pre="nucleocapsid proteins function as interferon antagonistsJ. Virol.81200754855710.1128/jvi.01782-0617108024 LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
 <result pre="the epidemic and the challengesInt. J. Antimicrob. Agents55202010592410.1016/j.ijantimicag.2020.10592432081636 LiuY.-J.IPC: professional" exact="type 1" post="interferon-producing cells and plasmacytoid dendritic cell precursorsAnnu. Rev. Immunol.23200527530610.1146/annurev.immunol.23.021704.11563315771572"/>
 <result pre="and plasmacytoid dendritic cell precursorsAnnu. Rev. Immunol.23200527530610.1146/annurev.immunol.23.021704.11563315771572 LokugamageK.G.SchindewolfC.MenacheryV.D.SARS-CoV-2 sensitive to" exact="type I" post="interferon pretreatmentBioRxiv202010.1101/2020.03.07.982264 LoutfyM.R.BlattL.M.SiminovitchK.A.WardS.WolffB.LhoH.PhamD.H.DeifH.LaMereE.A.ChangM.KainK.C.FarcasG.A.FergusonP.LatchfordM.LevyG.DennisJ.W.LaiE.K.Y.FishE.N.Interferon alfacon-1 plus corticosteroids in severe acute"/>
 <result pre="type I interferon pretreatmentBioRxiv202010.1101/2020.03.07.982264 LoutfyM.R.BlattL.M.SiminovitchK.A.WardS.WolffB.LhoH.PhamD.H.DeifH.LaMereE.A.ChangM.KainK.C.FarcasG.A.FergusonP.LatchfordM.LevyG.DennisJ.W.LaiE.K.Y.FishE.N.Interferon alfacon-1 plus corticosteroids in severe" exact="acute" post="respiratory syndrome: a preliminary studyJ. Am. Med. Assoc.29020033222322810.1001/jama.290.24.3222 LuH.Drug"/>
 <result pre="I interferon pretreatmentBioRxiv202010.1101/2020.03.07.982264 LoutfyM.R.BlattL.M.SiminovitchK.A.WardS.WolffB.LhoH.PhamD.H.DeifH.LaMereE.A.ChangM.KainK.C.FarcasG.A.FergusonP.LatchfordM.LevyG.DennisJ.W.LaiE.K.Y.FishE.N.Interferon alfacon-1 plus corticosteroids in severe acute" exact="respiratory" post="syndrome: a preliminary studyJ. Am. Med. Assoc.29020033222322810.1001/jama.290.24.3222 LuH.Drug treatment"/>
 <result pre="humansPharm. Res. (N. Y.)191020021537154310.1023/A:1020468902694 MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob. Agents Chemother.1â€&quot;18202010.1128/AAC.00399-20 MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and restoration of severe"/>
 <result pre="respiratory 2019 coronavirusAntimicrob. Agents Chemother.1â€&quot;18202010.1128/AAC.00399-20 MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and restoration of severe" exact="acute" post="respiratory syndrome coronavirus mutant lacking 2â€™-O-methyltransferase activityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 MorgensternB.MichaelisM.BaerP.C.DoerrH.W.CinatlJ.Ribavirin"/>
 <result pre="2019 coronavirusAntimicrob. Agents Chemother.1â€&quot;18202010.1128/AAC.00399-20 MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and restoration of severe acute" exact="respiratory" post="syndrome coronavirus mutant lacking 2â€™-O-methyltransferase activityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 MorgensternB.MichaelisM.BaerP.C.DoerrH.W.CinatlJ.Ribavirin and"/>
 <result pre="coronavirusAntimicrob. Agents Chemother.1â€&quot;18202010.1128/AAC.00399-20 MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and restoration of severe acute respiratory" exact="syndrome" post="coronavirus mutant lacking 2â€™-O-methyltransferase activityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 MorgensternB.MichaelisM.BaerP.C.DoerrH.W.CinatlJ.Ribavirin and interferon-Î²"/>
 <result pre="Res. Commun.326200590590810.1016/j.bbrc.2004.11.12815607755 OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221"/>
 <result pre="Commun.326200590590810.1016/j.bbrc.2004.11.12815607755 OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221 RanieriV.M.PettilÃ¤V.KarvonenM.K.JalkanenJ.NightingaleP.BrealeyD.ManceboJ.FerrerR.MercatA.PatronitiN.QuintelM.VincentJ.L.OkkonenM.MezianiF.BellaniG.MacCallumN.CreteurJ.KlugeS.Artigas-RaventosA.MaksimowM.PiippoI.ElimaK.JalkanenS.JalkanenM.BellinganG.Effect"/>
 <result pre="free from mechanical ventilation among patients with moderate to severe" exact="acute" post="respiratory distress syndrome: a randomized clinical trialJAMA, J. Am."/>
 <result pre="from mechanical ventilation among patients with moderate to severe acute" exact="respiratory" post="distress syndrome: a randomized clinical trialJAMA, J. Am. Med."/>
 <result pre="Assoc.323202072573310.1001/jama.2019.22525 SainzB.MosselE.C.PetersC.J.GarryR.F.Interferon-beta and interferon-gamma synergistically inhibit the replication of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV)Virology3292004111710.1016/j.virol.2004.08.01115476870 SamuelC.E.Antiviral actions of interferonsClin. Microbiol."/>
 <result pre="SainzB.MosselE.C.PetersC.J.GarryR.F.Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV)Virology3292004111710.1016/j.virol.2004.08.01115476870 SamuelC.E.Antiviral actions of interferonsClin. Microbiol. Rev.14200177880910.1128/CMR.14.4.778-809.200111585785"/>
 <result pre="Rev.14200177880910.1128/CMR.14.4.778-809.200111585785 ScagnolariC.VicenziE.BellomiF.StillitanoM.G.PinnaD.PoliG.ClementiM.DianzaniF.AntonelliG.Increased sensitivity of SARS-coronavirus to a combination of human" exact="type I" post="and type II interferonsAntivir. Ther.920041003101115651759 SchneiderW.M.ChevillotteM.D.RiceC.M.Interferon-stimulated genes: a complex"/>
 <result pre="of SARS-coronavirus to a combination of human type I and" exact="type II" post="interferonsAntivir. Ther.920041003101115651759 SchneiderW.M.ChevillotteM.D.RiceC.M.Interferon-stimulated genes: a complex web of host"/>
 <result pre="or IFN-Î²1a in combination with ribavirin to treat Middle East" exact="respiratory" post="syndrome coronavirus pneumonia: a retrospective studyJ. Antimicrob. Chemother.7020152129213210.1093/jac/dkv08525900158 SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.SpahnJ.E.BauerL.SellersS.PorterD.FengJ.Y.CihlarT.JordanR.DenisonM.R.BaricR.S.Comparative"/>
 <result pre="IFN-Î²1a in combination with ribavirin to treat Middle East respiratory" exact="syndrome" post="coronavirus pneumonia: a retrospective studyJ. Antimicrob. Chemother.7020152129213210.1093/jac/dkv08525900158 SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.SpahnJ.E.BauerL.SellersS.PorterD.FengJ.Y.CihlarT.JordanR.DenisonM.R.BaricR.S.Comparative therapeutic"/>
 <result pre="against MERS-CoVNat. Commun.11202010.1038/s41467-019-13940-6 ShenK.L.YangY.H.Diagnosis and treatment of 2019 novel coronavirus" exact="infection" post="in children: a pressing issueWorld J. Pediatr.20206810.1007/s12519-020-00344-6 SiddiqiH.K.MehraM.R.COVID-19 illness"/>
 <result pre="illness in native and immunosuppressed states: a clinical-therapeutic staging proposalJ." exact="Heart" post="Lung Transplant.2020 StockmanL.J.BellamyR.GarnerP.SARS: systematic review of treatment effectsPLoS Med.320061525153110.1371/journal.pmed.0030343"/>
 <result pre="Factor Rev.19200812113210.1016/j.cytogfr.2008.01.00118321765 ToturaA.L.BaricR.S.SARS coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferonCurr. Opin. Virol.2201226427510.1016/j.coviro.2012.04.00422572391 ZhangW.ZhaoY.ZhangF.WangQ.LiT.LiuZ.WangJ.QinY.ZhangX.YanX.ZengX.ZhangS.The use of anti-inflammatory"/>
 <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the perspectives of clinical immunologists from ChinaClin."/>
 <result pre="ZhaoZ.ZhangF.XuM.HuangK.ZhongW.CaiW.YinZ.HuangS.DengZ.WeiM.XiongJ.HawkeyP.M.Description and clinical treatment of an early outbreak of severe" exact="acute" post="respiratory syndrome (SARS) in Guangzhou, PR ChinaJ. Med. Microbiol.52200371572010.1099/jmm.0.05320-012867568"/>
 <result pre="and clinical treatment of an early outbreak of severe acute" exact="respiratory" post="syndrome (SARS) in Guangzhou, PR ChinaJ. Med. Microbiol.52200371572010.1099/jmm.0.05320-012867568 ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.GuanL.WeiY.LiH.WuX.XuJ.TuS.ZhangY.ChenH.Clinical"/>
 <result pre="clinical treatment of an early outbreak of severe acute respiratory" exact="syndrome" post="(SARS) in Guangzhou, PR ChinaJ. Med. Microbiol.52200371572010.1099/jmm.0.05320-012867568 ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.GuanL.WeiY.LiH.WuX.XuJ.TuS.ZhangY.ChenH.Clinical course"/>
 <result pre="Med. Microbiol.52200371572010.1099/jmm.0.05320-012867568 ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.GuanL.WeiY.LiH.WuX.XuJ.TuS.ZhangY.ChenH.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="Florence Ader. Scientific coordinator: Yazdan Yazdanpanah. Chief methodologist: France Mentre." exact="Infectious" post="diseases specialists: FranÃ§ois-Xavier Lescure, Nathan Peiffer-Smadja. Intensivists: Lila Bouadma,"/>
 <result pre="Bruno Lina, Florence Morfin-Sherpa. Pharmacologist: Gilles Peytavin. Genetic: Laurent Abel." exact="Viral" post="modeling: Jeremie Guedj. Clinical Trial Unit: Methodologists: Charles Burdet,"/>
 <result pre="LaÃ«titia Moinot, Linda Wittkop. ANRS coordination and Pharmacovigilance: Carole Cagnot," exact="Alpha" post="Diallo, Soizic Le Mestre, Delphine Lebrasseur-Longuet, Noemie Mercier, Ventzislava"/>
</results>
